Marshall Wace LLP Purchases 4,855 Shares of Certara, Inc. (NASDAQ:CERT)

Marshall Wace LLP boosted its holdings in Certara, Inc. (NASDAQ:CERT) by 11.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 47,855 shares of the company’s stock after buying an additional 4,855 shares during the quarter. Marshall Wace LLP’s holdings in Certara were worth $510,000 at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in the business. Brown Brothers Harriman & Co. raised its stake in shares of Certara by 63.8% during the fourth quarter. Brown Brothers Harriman & Co. now owns 3,818,613 shares of the company’s stock valued at $40,668,000 after acquiring an additional 1,487,998 shares during the last quarter. Bank of New York Mellon Corp raised its position in Certara by 169.0% during the 4th quarter. Bank of New York Mellon Corp now owns 1,995,071 shares of the company’s stock worth $21,248,000 after purchasing an additional 1,253,385 shares during the last quarter. ExodusPoint Capital Management LP acquired a new position in Certara during the 4th quarter worth about $11,542,000. Teacher Retirement System of Texas grew its position in shares of Certara by 13.9% in the 4th quarter. Teacher Retirement System of Texas now owns 4,557,951 shares of the company’s stock valued at $48,542,000 after buying an additional 557,348 shares during the last quarter. Finally, Raymond James Financial Inc. acquired a new stake in shares of Certara in the fourth quarter valued at about $3,628,000. 73.96% of the stock is currently owned by institutional investors and hedge funds.

Certara Price Performance

CERT stock opened at $12.99 on Friday. Certara, Inc. has a 1 year low of $8.64 and a 1 year high of $17.94. The stock has a market capitalization of $2.10 billion, a PE ratio of -64.95, a price-to-earnings-growth ratio of 9.29 and a beta of 1.64. The company’s 50-day moving average is $11.70 and its 200-day moving average is $11.65. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.86 and a quick ratio of 2.86.

Wall Street Analyst Weigh In

A number of research firms recently commented on CERT. TD Cowen began coverage on Certara in a research note on Thursday, February 27th. They issued a “buy” rating and a $16.00 price objective on the stock. Robert W. Baird upped their price objective on shares of Certara from $9.00 to $13.00 and gave the company a “neutral” rating in a research note on Friday, April 11th. KeyCorp lifted their target price on shares of Certara from $15.00 to $18.00 and gave the stock an “overweight” rating in a research note on Wednesday, April 16th. Stephens reaffirmed an “overweight” rating and set a $17.00 price target on shares of Certara in a research report on Thursday, February 27th. Finally, Barclays lowered their price objective on Certara from $13.00 to $11.00 and set an “equal weight” rating for the company in a research report on Thursday, April 10th. Four research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $15.17.

Certara Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.